Search results
Showing 76 to 90 of 92 results for atezolizumab
Discontinued Reference number: GID-TA11163
Discontinued Reference number: GID-TA11089
In development Reference number: GID-TA11021 Expected publication date: TBC
Discontinued Reference number: GID-TA11165
Discontinued Reference number: GID-TA10933
In development Reference number: GID-TA10777 Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 739.
In development Reference number: GID-TA11654 Expected publication date: TBC
Discontinued Reference number: GID-TA11180
In development Reference number: GID-TA11278 Expected publication date: TBC
Early and locally advanced breast cancer: diagnosis and management (NG101)
This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment
Today, for the first time, we have given the green light to a targeted treatment for the most common form of bladder cancer.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer
Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer